Hikma Pharmaceuticals USA Inc. 2022-08-17 Health serious FDA
Health · FDA · Recall #FDA-D-1309-2022
Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vial per carton, Rx Only, Novaplus,… Recall
Issued August 17, 2022 · Hikma Pharmaceuticals USA Inc.
In August 2022, Hikma Pharmaceuticals USA Inc. recalled the Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vial per carton, Rx Only, Novaplus,…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
What you should do
- 1 Stop using Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vial per carton, Rx Only, Novaplus,… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Hikma Pharmaceuticals USA Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Hikma Pharmaceuticals USA Inc.
- Category
- Health
- Recall date
- August 17, 2022
- Units affected
- Not reported
- Sold at
- Nationwide in the USA
- Recall number
- FDA-D-1309-2022
- Made in
- United States
- Issuing agency
- FDA
In context
- Hikma Pharmaceuticals USA Inc. has 2 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 870th Health recall we've logged in 2022.